Literature DB >> 18077706

Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein.

Berend Jan Bosch1, John W A Rossen, Willem Bartelink, Stephanie J Zuurveen, Cornelis A M de Haan, Stephane Duquerroy, Charles A B Boucher, Peter J M Rottier.   

Abstract

Peptides based on heptad repeat (HR) domains of class I viral fusion proteins are considered promising antiviral drugs targeting virus cell entry. We have analyzed the evolution of the mouse hepatitis coronavirus during multiple passaging in the presence of an HR2-based fusion inhibitor. Drug-resistant variants emerged as a result of multiple substitutions in the spike fusion protein, notably within a 19-residue segment of the HR1 region. Strikingly, one mutation, an A1006V substitution, which consistently appeared first in four independently passaged viruses, was the main determinant of the resistance phenotype, suggesting that only limited options exist for escape from the inhibitory effect of the HR2 peptide.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077706      PMCID: PMC2258948          DOI: 10.1128/JVI.02287-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

2.  Inhibition of human coronavirus NL63 infection at early stages of the replication cycle.

Authors:  Krzysztof Pyrc; Berend Jan Bosch; Ben Berkhout; Maarten F Jebbink; Ronald Dijkman; Peter Rottier; Lia van der Hoek
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  HIV-1 inhibition by a peptide.

Authors:  S Jiang; K Lin; N Strick; A R Neurath
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

4.  Coronaviruses as vectors: position dependence of foreign gene expression.

Authors:  Cornelis A M de Haan; Linda van Genne; Jeroen N Stoop; Haukeline Volders; Peter J M Rottier
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex.

Authors:  Berend Jan Bosch; Ruurd van der Zee; Cornelis A M de Haan; Peter J M Rottier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.

Authors:  Stephen A Gallo; Kelly Sackett; Satinder S Rawat; Yechiel Shai; Robert Blumenthal
Journal:  J Mol Biol       Date:  2004-06-25       Impact factor: 5.469

7.  Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.

Authors:  Berend Jan Bosch; Byron E E Martina; Ruurd Van Der Zee; Jean Lepault; Bert Jan Haijema; Cees Versluis; Albert J R Heck; Raoul De Groot; Albert D M E Osterhaus; Peter J M Rottier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-18       Impact factor: 11.205

8.  Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein.

Authors:  Kehu Yuan; Ling Yi; Jian Chen; Xiuxia Qu; Tingting Qing; Xi Rao; Pengfei Jiang; Jianhe Hu; Zikai Xiong; Yuchun Nie; Xuanling Shi; Wei Wang; Chen Ling; Xiaolei Yin; Keqiang Fan; Luhua Lai; Mingxiao Ding; Hongkui Deng
Journal:  Biochem Biophys Res Commun       Date:  2004-07-02       Impact factor: 3.575

9.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.

Authors:  Shuwen Liu; Gengfu Xiao; Yibang Chen; Yuxian He; Jinkui Niu; Carlos R Escalante; Huabao Xiong; James Farmar; Asim K Debnath; Po Tien; Shibo Jiang
Journal:  Lancet       Date:  2004-03-20       Impact factor: 79.321

10.  Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core.

Authors:  Yanhui Xu; Yiwei Liu; Zhiyong Lou; Lan Qin; Xu Li; Zhihong Bai; Hai Pang; Po Tien; George F Gao; Zihe Rao
Journal:  J Biol Chem       Date:  2004-04-27       Impact factor: 5.157

View more
  9 in total

Review 1.  Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence.

Authors:  Taylor Heald-Sargent; Tom Gallagher
Journal:  Viruses       Date:  2012-04-12       Impact factor: 5.048

Review 2.  Drug targets for COVID-19 therapeutics: Ongoing global efforts.

Authors:  Ambrish Saxena
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

3.  Biochemical Analysis of Coronavirus Spike Glycoprotein Conformational Intermediates during Membrane Fusion.

Authors:  Miyuki Kawase; Michiyo Kataoka; Kazuya Shirato; Shutoku Matsuyama
Journal:  J Virol       Date:  2019-09-12       Impact factor: 5.103

Review 4.  Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance.

Authors:  Julian W Tang; Tommy T Lam; Hassan Zaraket; W Ian Lipkin; Steven J Drews; Todd F Hatchette; Jean-Michel Heraud; Marion P Koopmans
Journal:  Lancet Infect Dis       Date:  2017-04-28       Impact factor: 25.071

5.  Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides.

Authors:  Jung-Eun Park; Tom Gallagher
Journal:  Virology       Date:  2017-08-10       Impact factor: 3.616

Review 6.  COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.

Authors:  B Robson
Journal:  Comput Biol Med       Date:  2020-04-11       Impact factor: 4.589

Review 7.  Topology and biological function of enterovirus non-structural protein 2B as a member of the viroporin family.

Authors:  Da Ao; Shi-Qi Sun; Hui-Chen Guo
Journal:  Vet Res       Date:  2014-08-28       Impact factor: 3.683

8.  Evaluating MERS-CoV Entry Pathways.

Authors:  Enya Qing; Michael P Hantak; Gautami G Galpalli; Tom Gallagher
Journal:  Methods Mol Biol       Date:  2020

9.  Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus.

Authors:  B Robson
Journal:  Comput Biol Med       Date:  2020-02-26       Impact factor: 4.589

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.